Literature DB >> 23998723

Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen?

Dev Karan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23998723      PMCID： PMC5242386          DOI： 10.2217/imt.13.83

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  20 in total

Review 1.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

2.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

Authors:  R E Reiter; Z Gu; T Watabe; G Thomas; K Szigeti; E Davis; M Wahl; S Nisitani; J Yamashiro; M M Le Beau; M Loda; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

Review 3.  Is prostate-specific membrane antigen a multifunctional protein?

Authors:  Ayyappan K Rajasekaran; Gopalakrishnapillai Anilkumar; Jason J Christiansen
Journal:  Am J Physiol Cell Physiol       Date:  2005-05       Impact factor: 4.249

4.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

Authors:  G L Wright; B M Grob; C Haley; K Grossman; K Newhall; D Petrylak; J Troyer; A Konchuba; P F Schellhammer; R Moriarty
Journal:  Urology       Date:  1996-08       Impact factor: 2.649

5.  Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

Authors:  David M Lubaroff; Badrinath R Konety; Brian Link; Jack Gerstbrein; Tammy Madsen; Mary Shannon; Jeanne Howard; Jennifer Paisley; Diana Boeglin; Timothy L Ratliff; Richard D Williams
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

6.  Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.

Authors:  Douglas G McNeel; Edward J Dunphy; James G Davies; Thomas P Frye; Laura E Johnson; Mary Jane Staab; Dorothea L Horvath; Jane Straus; Dona Alberti; Rebecca Marnocha; Glenn Liu; Jens C Eickhoff; George Wilding
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

Review 7.  Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

Authors:  Hans Lilja; David Ulmert; Andrew J Vickers
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

8.  DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.

Authors:  Lindsey Chudley; Katy McCann; Ann Mander; Torunn Tjelle; Juan Campos-Perez; Rosemary Godeseth; Antonia Creak; James Dobbyn; Bernadette Johnson; Paul Bass; Catherine Heath; Paul Kerr; Iacob Mathiesen; David Dearnaley; Freda Stevenson; Christian Ottensmeier
Journal:  Cancer Immunol Immunother       Date:  2012-05-22       Impact factor: 6.968

9.  Prostate-specific membrane antigen-based therapeutics.

Authors:  Naveed H Akhtar; Orrin Pail; Ankeeta Saran; Lauren Tyrell; Scott T Tagawa
Journal:  Adv Urol       Date:  2011-07-17

10.  Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.

Authors:  Nadeem A Sheikh; Daniel Petrylak; Philip W Kantoff; Corazon Dela Rosa; Frances P Stewart; Ling-Yu Kuan; James B Whitmore; James B Trager; Christian H Poehlein; Mark W Frohlich; David L Urdal
Journal:  Cancer Immunol Immunother       Date:  2012-08-03       Impact factor: 6.968
View more
  3 in total

1.  PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.

Authors:  Yael Langut; Alaa Talhami; Samarasimhareddy Mamidi; Alexei Shir; Maya Zigler; Salim Joubran; Anna Sagalov; Efrat Flashner-Abramson; Nufar Edinger; Shoshana Klein; Alexander Levitzki
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

Review 2.  Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress.

Authors:  John C Flickinger; Ulrich Rodeck; Adam E Snook
Journal:  Vaccines (Basel)       Date:  2018-07-25

Review 3.  Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?

Authors:  Nicholas A Zorko; Charles J Ryan
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-05-25       Impact factor: 5.554
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.